tbuckley/cabot-search huggingface dataset:
Correction
Journal: BMJ (1962)

ANY QUESTIONS ?especially when local conditions are such that expert help and adequate facilities for breech delivery are not always available.Probably most obstetricians to-day use general anaesthesia for external version only in special cases, such as when there is a question of possible disproportion which could be much more easily assessed if the head were presenting.Sceptics have suggested that the incidence of breech presentation in labour is the same whether or not routine external version is practised antenatally, but this has been disproved.6
Liver fibrosis
Authors: Ramón Bataller, David A. Brenner
Journal: Journal of Clinical Investigation (2005)

Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Our knowledge of the cellular and molecular mechanisms of liver fibrosis has greatly advanced. Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver. These cells are activated by fibrogenic cytokines such as TGF-β1, angiotensin II, and leptin. Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins. Although many therapeutic interventions are effective in experimental models of liver fibrosis, their efficacy and safety in humans is unknown. This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.
Taux de détection d’adénome supérieur avec l’Endocuff: résultats d’un essai randomisé
Journal: Endoscopy (2017)

De nombreuses techniques ont été proposées afin d’améliorer la vision de l’endoscopiste et améliorer la détection des polypes et des adénomes. L’Endocuff est un capuchon mousse en polymère à usage unique et stérile, qui est placé à la pointe de l’endoscope afin d’améliorer la visualisation de la muqueuse lors de la coloscopie en déplissant les plis coliques. Le but de l’étude était de comparer le taux de détection des adénomes (TDA) de la coloscopie assistée par Endocuff à celui de la coloscopie conventionnelle. Gonzalez-Fernandez et al. ont mené un essai prospectif randomisé monocentrique à Mexico d’avril 2014 à novembre 2015, incluant des patients de plus de 50 ans ayant leur première coloscopie de dépistage, réalisée avec des coloscopes FUJIFILM ou OLYMPUS, par 6 séniors ou 12 internes encadrés par ces mêmes séniors.
Acknowledgement Omitted
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract A2-42: Identifying clinically important somatic mutations through a knowledge-based approach
Authors: Benjamin J. Ainscough, Malachi Griffith, Jason Kunisaki, Adam Coffman, Joshua F. McMichael, James M. Eldred, Jason R. Walker, Robert S. Fulton, Richard K. Wilson, Obi L. Griffith, Elaine R. Mardis
Journal: Cancer Research (2015)

Abstract Large-scale tumor sequencing projects, like The Cancer Genome Atlas (TCGA), have implicated thousands of somatic mutations in cancer. These initiatives have incentivized many improvements in somatic variant detection. However, we have observed that important pathogenic variants are often missed due to stringent filtering, tumor heterogeneity, tumor contamination of normal, low tumor purity, alignment challenges, and other issues. These idiosyncrasies can impede variant detection algorithms from reliably calling even the most clinically relevant variants. To rescue this missed variation we devised a knowledge based variant identification strategy. We mined the literature and other variant databases for pathogenic variation and assembled them into an integrated Database of Curated Mutations(DoCM - www.docm.info). The DoCM contains 488 variants across 63 genes implicated in 34 cancer types. We developed an algorithm to identify any pathogenic variant signal, for all variants in the DoCM, in aligned sequence data. As a proof of principle, we applied this approach to four cancer types sequenced by TCGA: acute myeloid leukemia (AML), breast cancer, ovarian carcinoma, and uterine corpus endometrial carcinoma. Obvious sequencing and alignment errors, like variants in homopolymer runs, were excluded from subsequent analysis by manual review. Across these four TCGA projects, which includes 1,840 individuals, 1,757 clinically relevant variants were identified, 1,223 of which had not been previously reported in TCGA studies. To validate this approach, custom capture probes were designed for all of the DoCM variants, new libraries constructed and deep sequencing performed on 96 tumor and matched normal samples from the AML and breast cancer TCGA projects. Following this strategy, we were able to confirm the rescue of clinically relevant somatic mutations that were missed in the original TCGA analysis. We propose a knowledge-driven variant detection approach be considered as standard practice to avoid false-negative calls of events likely to be clinically relevant. Citation Format: Benjamin J. Ainscough, Malachi Griffith, Jason Kunisaki, Adam Coffman, Joshua F. McMichael, James M. Eldred, Jason R. Walker, Robert S. Fulton, Richard K. Wilson, Obi L. Griffith, Elaine R. Mardis. Identifying clinically important somatic mutations through a knowledge-based approach. [abstract]. In: Proceedings of the AACR Special Conference on Translation of the Cancer Genome; Feb 7-9, 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 1):Abstract nr A2-42.
Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States.
Authors: Roman Casciano, Maruit Chulikavit, Allison Perrin, Zhimei Liu, Xufang Wang, Joseph Babigumira, Louis P Garrison
Journal: Journal of Clinical Oncology (2012)

226 Background: Everolimus and sunitinib were recently approved to treat patients with advanced, progressive pancreatic neuroendocrine tumors (pNETs). This analysis examines the projected cost-effectiveness of everolimus versus sunitinib in this setting from a US payer perspective. Methods: A lifetime Markov model was developed to simulate a cohort of advanced, progressive pNET patients and to estimate the cost per incremental life-years gained (LYG) and quality-adjusted life years (QALYs) gained when treating with everolimus as compared to sunitinib. Absent head-to-head trials, efficacy data were based on a weight-adjusted indirect comparison of the two agents using the respective phase 3 trial data. Disease or health states considered in the model included: stable disease without adverse events, stable disease with adverse events, disease progression, and death. Costs of anti-tumor therapies, symptomatic care drugs, and post-progression therapy were based on wholesale acquisition cost. Other costs including physician visits, tests, infusions, hospitalizations, adverse event costs, and end-of-life care costs were obtained from literature and/or standard sources such as the Healthcare Cost and Utilization Project and Medicare reimbursement rates. Utility inputs were based on a UK time trade-off study. Sensitivity analyses were conducted to test the model’s robustness. Results: In the base case analysis, the estimated gain of everolimus over sunitinib was 0.448 LYs (0.304 QALYs) at an incremental cost of $12,673, resulting in an incremental cost-effectiveness ratio (ICER) of $28,281/LYG ($41,702/QALY gained), which fell within the cost per QALY range for many other widely used oncology drugs. The analysis was sensitive to the uncertainty of the sunitinib trial results; however, a probabilistic sensitivity analysis showed the results were consistent across simulations. Conclusions: While the analysis is limited by its reliance on an indirect comparison of two phase 3 studies rather than a single head-to-head trial, everolimus is expected to be cost-effective relative to sunitinib in advanced pNET.
Studies on Factors Influencing the Transmission of Onchocerciasis: II. Intake of Onchocerca Volvulus Microfilariae by Simulium Damnosum and Survival of the Parasites in the Fly Under Laboratory Conditions
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What's new this month in BMJ Journals
Authors: Harvey Marcovitch
Journal: BMJ (2006)

A controlled trial of pneumococccal vaccine (Pneumo23; Aventis Pasteur MSD) in 600 patients with chronic obstructive pulmonary disease (COPD) in Spain has shown that it protected people aged over 65 from pneumonia over the three year period of the study, with an effectiveness of 76%. It was particularly protective in those with severe airflow obstruction. However, there was no difference in mortality (about 19%) nor any significant difference for people under 65. The authors call for further studies in younger and more mildly affected patients to define the precise role of the vaccine. Thorax 2006;61: 189–195 [OpenUrl][1][Abstract/FREE Full Text][2] A survey in New Zealand has shown that only 0.4% of reported adverse events result in a complaint to the country's health and disability commissioner, the gateway to its “no-fault” (tort-free) compensation system. Contrary to statements frequently repeated in the lay media, fewer than 1% … [1]: {openurl}?query=rft_id%253Dinfo%253Adoi%252F10.1136%252Fthx.2005.043323%26rft_id%253Dinfo%253Apmid%252F16227328%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/ijlink?linkType=ABST&journalCode=thoraxjnl&resid=61/3/189&atom=%2Fbmj%2F332%2F7546%2F904.atom
SAT0104 The role of prolactin, as sex hormone, and its receptor involved in rheumatoid arthritis:
Authors: M.W. Tang, D.M. Gerlag, V. Codullo, E.C. Vieina de Sousa, A.Q. Reuwer, M. Twickler, R.B. Landewé, P.P. Tak
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) mainly affects women. Prolactin (PRL) is a sex hormone with immunomodulatory properties. High prolactin levels are associated with increased disease activity postpartum, and that the PRL-inhibitor bromocriptine improves disease activity of patients with RA. Hyperprolactinemia is observed in 6% of RA-patients, compared to 3% of healthy individuals. The prolactin receptor (PRLR), belonging to the family of cytokine receptors, has been described in atherosclerotic plaques, mainly on macrophages. <h3>Objectives</h3> The objective of the study is to determine 1) the level of PRL in RA-patients related to treatment effect 2) PRLR expression in synovial tissue of RA, psoriatic arthritis (PsA) and osteoarthritis (OA) patients 3) the phenotype of the PRLR expressing cell. <h3>Methods</h3> Serum prolactin levels were measured using immunofluorescent metric assay in patients with RA before TNF-α blockade (n=98). The expression of PRLR was determined in synovial tissue (ST) of RA (n=91), PsA (n=15) and OA (n=9) patients using digital image analysis. Immunofluorescence (IF) was used to detect the PRLR expressing cell type. <h3>Results</h3> Hyperprolactinemia (PRL-level: 16-24 μg/L) was found in 3.8% of the patients with RA. Prolactin levels were highest in premenopausal compared to postmenopausal females and males. Baseline PRL-levels were significantly lower in responders (median (range): 7.0 (2.0-24) μg/L) than in non-responders (9.3 (4.0-19) μg/L)) on TNF treatment (P=0.009). Higher tertiles of PRL (but within the physiological range) were associated with RF-positivity (P=0.005), aCCP-positivity (P=0.06) and erosive disease (P=0.024). After adjustment for these potential confounders, and for baseline-DAS28, baseline-PRL appeared to be a predictor of non-response to anti-TNF treatment (OR: 4.5; P=0.018; table 1). RF and aCCP did not independently contribute. The proportion of patients expressing PRLR in the synovium was similar in RA (66%) and PsA (73%) patients, and lower in OA patients (25%; P=0.05). PRLR expression was higher in RA (median (range): 0.055 (0.000-5.673) IOD/nuclei/mm<sup>2</sup>) and PsA (0.182 (0.000-5.336)) compared to OA (0.000 (0.000-0.908); P=0.024). Males and (pre-/postmenopausal) females had similar PRLR expression. Using IF, co-localisation was observed with macrophages and endothelial cells. <h3>Conclusions</h3> Higher levels of PRL independently predicts a non-response to anti-TNF treatment. The expression of the PRLR in synovial tissue, mainly by macrophages, is higher in the inflammatory diseases (RA and PsA) than in OA. Our combined data suggest an important role of prolactin and its receptor in RA. <h3>Disclosure of Interest</h3> None Declared
Reply
Authors: S. Adam Strickberger, D. Woodrow Benson, Italo Biaggioni, David J. Callans, Mitchell I. Cohen, Kenneth A. Ellenbogen, Andrew E. Epstein, Paul Friedman, Jeffrey Goldberger, Paul A. Heidenreich, George J. Klein, Bradley P. Knight, Carlos A. Morillo, Robert J. Myerburg, Cathy A. Sila, Mary A. Woo
Journal: Journal of the American College of Cardiology (2006)
Correction.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
[unk] for Medical Writing: A Useful Guide to Principles and Practice of Effective Scientific Writing and Illustration
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
O10: The Green Initiative: improving environmentally sustainable practice and optimizing waste management in a dermatology department
Authors: E Ang, R Abbott, Isherwood Wilkinson
Journal: British Journal of Dermatology (2021)

drawn from a large network of general practices distributed across England, currently covering a registered population of 2Á6 million people, with and without a diagnosis of AA.The incidence and prevalence of AA in children and adults in England over 2009-18 were estimated.Variation in AA by sex, socioeconomic status, geographical distribution and ethnicity were examined; primary care visits, specialist dermatology review rates and prescribing of medications indicated for AA, in the first year after AA diagnosis, were evaluated.AA incidence was 0Á26 cases per 1000 person-years.AA prevalence in adults was 0Á6%, with a slightly higher prevalence in females [0Á6%, 95% confidence interval [CI] 0Á60-0Á63) than males (0Á55%, 95% CI 0Á53-0Á56).AA onset peaked at the age of 25-29 years for both sexes, although the peak was broader in females.People of Asian, black and mixed ethnicities were more likely to present with AA, especially those of Asian ethnicity [incidence rate ratio (IRR) 3Á32, 95% CI 3Á11-3Á55].Higher AA incidence was associated with social deprivation (IRR most vs. least deprived quintile 1Á47, 95% CI 1Á37-1Á59) and urban living (IRR 1Á23, 95% CI 1Á14-1Á32).In the year after diagnosis, people with AA had high rates of primary care visits [average 4Á32 visits (95% CI 4Á27-4Á38) per year vs. 2Á58 visits (95% CI 2Á56-2Á60) in matched controls] and specialist dermatology referrals (24% of AA patients referred), but people of higher social deprivation were less likely to be referred for specialist dermatology review.Potent topical corticosteroids were the most commonly prescribed medications in the year after AA diagnosis, and prescribing increased over the study period (23Á6% in 2009 vs. 33Á1% in 2017).Forty-six per cent of patients did not receive any prescription medication.We present a comprehensive overview of AA in England, including incidence, point prevalence, sociodemographic associations, patterns of prescribing and healthcare utilization.The findings from this study will help clinicians to identify those most likely to develop AA.It also highlights important healthcare inequalities in the management of AA.
Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use
Authors: P. Wolner-Hanssen
Journal: JAMA (1990)

Studies have shown that oral contraceptive use may protect against pelvic inflammatory disease (PID), but it is not known whether oral contraceptives protect against the disease among women already infected with<i>Chlamydia trachomatis or Neisseria gonorrhoeae</i>. The relationship between oral contraceptive use and PID was analyzed in a case-control study of 141 women with verified PID and 739 randomly selected, sexually active women with no clinical evidence of the disease. Case and control subjects were stratified on the basis of infection with<i>C trachomatis</i>,<i>N gonorrhoeae</i>, or neither organism. Among women infected with<i>C trachomatis</i>alone, those with PID were less likely than control subjects to use oral contraceptives. The association was significant when oral contraceptive use was compared with nonuse (odds ratio, 0.22; 95% confidence interval, 0.08 to 0.64) and with noncontraception (odds ratio, 0.17; 95% confidence interval, 0.06 to 0.53) and remained so after adjusting for potential confounding variables by logistic regression analysis. Among women infected with<i>N gonorrhoeae</i>alone, no association was found between use of oral contraceptives and PID. These data suggest that oral contraceptive use protects against symptomatic PID among women infected with<i>C trachomatis</i>but not among those infected with<i>N gonorrhoeae</i>. (<i>JAMA</i>. 1990;263:54-59)
<i>Annals</i> at 80: Still Young and Still Reaching Out
Journal: Annals of Internal Medicine (2007)

Editorials3 July 2007Annals at 80: Still Young and Still Reaching OutThe EditorsThe EditorsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-1-200707030-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This issue marks the beginning of the 80th year of publishing Annals of Internal Medicine. We hope our readers think that this octogenarian looks far younger than its chronological age. However, out of deference to the prerogatives of age, we present a modest celebration: a selective look forward at our strategy for remaining vital far into the future. People who stay vibrant well into old age stay connected with the world around them—think of a grandparent who learns to use such technologies as e-mail and instant messaging to stay connected with family and friends. Likewise, one of our main strategies ...Reference1. Laine C, Goodman SN, Griswold ME, Sox HC. Reproducible research: moving toward research the public can really trust. Ann Intern Med. 2007;146:450-3. [PMID: 17339612] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Disclosures: None disclosed.Corresponding Author: Customer Service, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 July 2007Volume 147, Issue 1Page: 65-66KeywordsClinical trialsForecastingHealth careMedical servicesPeer reviewQuality improvementScientistsStatistical dataSystematic reviewsTouch ePublished: 3 July 2007 Issue Published: 3 July 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...